1991
DOI: 10.1016/0304-3940(91)90061-w
|View full text |Cite
|
Sign up to set email alerts
|

Effects of D1 and D2 antagonists on the transient increase of dopamine release by dopamine agonists by means of brain dialysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
11
0

Year Published

2001
2001
2015
2015

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 15 publications
(12 citation statements)
references
References 19 publications
1
11
0
Order By: Relevance
“…Given the systemic application of the D1-R antagonist, we could not distinguish brain region and subcellular localization specific effects. Nevertheless, the very same D1-R antagonist we employed here, SCH23390, has been shown to reduce dopamine (Steketee, 1998; Kurata & Shibata, 1991) as well as serotonin release (Darbin et al, 2010) in mammals, results that are compatible with our finding of reduced DOPAC and 5HIAA levels in zebrafish. Furthermore, the level of neurotransmitter production has been shown to correlate with the level of their metabolites in mammals (Diop et al, 1988), which again is in line with our finding of reduced dopamine levels in response to the systemic D1-R antagonist treatment in zebrafish.…”
Section: Discussionsupporting
confidence: 89%
See 3 more Smart Citations
“…Given the systemic application of the D1-R antagonist, we could not distinguish brain region and subcellular localization specific effects. Nevertheless, the very same D1-R antagonist we employed here, SCH23390, has been shown to reduce dopamine (Steketee, 1998; Kurata & Shibata, 1991) as well as serotonin release (Darbin et al, 2010) in mammals, results that are compatible with our finding of reduced DOPAC and 5HIAA levels in zebrafish. Furthermore, the level of neurotransmitter production has been shown to correlate with the level of their metabolites in mammals (Diop et al, 1988), which again is in line with our finding of reduced dopamine levels in response to the systemic D1-R antagonist treatment in zebrafish.…”
Section: Discussionsupporting
confidence: 89%
“…Receptor occupancy, drug absorption, distribution, metabolism and excretion (ADME) studies have not been carried out in zebrafish for this particular drug, but based upon the mammalian literature (e.g. Cameron & Williams, 1993; Darbin et al, 2010; Steketee, 1998; Kurata & Shibata, 1991 and references therein) as well as on our own pilot behavioral studies, we found the 30 min exposure period to be sufficiently long for the drug to reach the zebrafish brain and exert behavioral effects. We also found the one hour long acclimation period to be sufficient for the fish to recover from any potential negative (fear inducing) consequences of the dosing procedure but not too long for the drug to wash out.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…Not surprisingly, the reverse microdialysis drug delivery method has provided a powerful technique for the study of local drug action and been used extensively in the brain and other tissues and has been thoroughly reviewed in the literature (Hocht et al, 2004, 2007; Plock and Kloft, 2005). The drug concentrations used in this study are 10-fold higher than those generally found in brain slice superfusion experiments, and were chosen to compensate for the spatial and temporal limitations associated with drug administration by reverse microdialysis, usually done in other studies (Hoebel et al, 1983; Johnson and Justice, 1983; Kurata and Shibata, 1991; Zornoza et al, 2005b; Rodriguez et al, 2008). …”
Section: Discussionmentioning
confidence: 99%